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HLA-DR Matching Effect in Orthotopic Liver Transplantation 
Under FK 506 
M. Kobayashi, A. Yagihashi, K. Noguchi, K. Terasawa, A. Konno, S. Hayashi, T.E. Starzl, and Y. Iwaki 
U NLIKE in kidney transplantation, graft survival was 
not influenced by the degree of HLA matching in 
human liver transplantation. In fact, our preliminary re-
sults revealed that 0 DR-matched liver transplant patients 
had inferior graft survival rates compared with those of 1 
or 2 DR-mismatched transplants. 1 
FK 506 is a new, powerful immunosuppressant, and it is 
effective for both liver and kidney transplantation.2 To 
study the effect of DR matching further in liver transplan-
tation, we analyzed the DR matching effect for patients 
under FK 506. 
MATERIALS AND METHODS 
This study consisted of a total of 772 patients who received 
orthotopic liver transplantation (OLTx) at the Presbyterian Uni-
versity Hospital (Pittsburgh, Pa) and the Pittsburgh Children 
Hospital from March 1989 to December 1991. All patients had first 
OLTxs with a negative T-lymphocyte crossmatch. The only 
patients precluded from the study were those who had simulta-
neous pancreas, kidney, or small intestine transplantation. In 
addition, 335 patients who had a first-cadaver kidney transplant 
during the same period were studied. Initial immunosuppressive 
drug therapy for both liver and kidney-transplanted patients 
consisted of either cyclosporine A (CyA) or FK 506 in combina-
tion with prednisone. Acute cellular rejection was treated with 
bolus methylprednisolone and/or OKT3. 
HLA typing was performed according to the standard National 
Institutes of Health method3 using an HLA typing tray obtained 
commercialIy (Gen Trak, Inc, Plymouth Meeting, Pa and One 
Lambda, Inc, Cannoga Park, CaliO. 
Both patient death and allograft removal, regardless of reasons, 
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were considered graft failure. Graft survival rates were computed 
by life table methods and generalized Wilcoxon test was used for 
the statistics. 
RESULTS 
The HLA-DR matching effect was clearly shown in ca-
daver kidney transplant patients whose initial immunosup-
pressant was CyA (Fig 1). Patients with a 0 DR-matched 
transplant had an 85% I-year graft survival rate, whereas 
patients with a I and 2 DR-mismatched transplant had 80% 
and 76% I-year survival rates, respectively. Although the 
best graft survival rate was still observed in patients with a 
o DR-mismatched transplant, the DR matching effect be-
came smaller when FK 506 was given as an initial immu-
nosuppressant. One-year graft survival rates for 0, 1, and 2 
DR-mismatched kidney transplant patients were 84%, 
85%, and 78%, respectively. 
In OLTx, 0 DR-matched transplant patients had the 
lowest survival rates regardless of their initial immunosup-
pressive drug (Fig 2). Interestingly, the best survival rate 
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Fig 1. Actuarial first-kidney graft survival rates according to the number of HLA DR-mismatched antigens under CyA or FK 506. (A) CyA; 
(8) FK 506. 
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Fig 2. Actuarial first·liver graft sUrvival rate according to the number of Hu\-DR mismatched antigens under CyA or FK 506. (A) CyA; 
(B) FK 506. 
was observed in patients with I DR-mismatched trans-
plants. 
DISCUSSION 
From this study, HLA-DR matching was clearly shown 
when patients were treated with Cy A in kidney transplant; 
however, its effect became smaller when FK 506 was used 
as an initial immunosuppressant. In OLTx patients, the 
DR matching effect was not obtained regardless of initial 
immunosuppressive drugs. The matching effect of histo-
compatibility antigens has been clearly demonstrated in 
experimental animal models; however, it should be noted 
that the most significant matching effect was observed in 
the transplant model without any immunosuppressant. 
The more the recipients are immunosuppressed, the less 
the effect of matching in histocompatibility antigens. In 
fact. the HLA matching effect was much clearer in the era 
of azathioprine compared with that observed in the era of 
Cy A. Since FK 506 seems to be a more potent immuno-
suppressant than CyA, it is possible that the HLA match· 
ing effect might be veiled under FK 506 treatment. Thus. 
the data presented in this study might simply reflect the 
strength of initial immunosuppressant and potency of FK 
506 in kidney transplantation. 
We failed to obtain the DR matching effect in OLTx. It 
is believed that the HLA matching effect would appear in 
chronic stage after the transplantation. However, a major· 
ity of the graft failures of OLTx patients in this study in 0 
DR-mismatched transplantation was seen within 3 post-
transplant months. Thus. it is possible that the phenome-
non which we observed in this study might not reflect the 
real HLA matching effect; the causes of failure in those 
patients must be further studied. 
REFERENCES 
1. Yagihashi A, Kobayashi M, Noguchi K, et a1: Transplant 
Proc (in press) 
2. Todo S, Nery J, Yanaga K, et a1: JAMA 261:711, 1989 
3. Zachary AA, Teresi GA (eds): ASH! Laboratory Manual. 
American Society for Histocompatibility and Immunogenetics. 
1990 
aq 
